# AstraDose
Anticancer drug dose adjuster for patients with multiple organ dysfunction syndrome

<strong>Table 1.</strong> Adaptation of anticancer drugs in patients with renal or hepatic impairment
<table>
 <tbody>
   <tr>
     <td><strong>N</strong></td>
     <td><strong>Medicines</strong></td>
     <td><strong>Renal impairment</strong></td>
     <td><strong>Hepatic impairment</strong></td>
   </tr>
   <tr>
     <td><strong>01</strong></td>
     <td>ACETATE D&rsquo;ABIRATERONE</td>
     <td>No adaptation</td>
     <td>No adaptation</td>
   </tr>
   <tr>
     <td><strong>02</strong></td>
     <td>ACIDE ZOLEDRONIQUE</td>
     <td>CrCl &lt; 35 mL/min: CI</td>
     <td>No adaptation</td>
   </tr>
   <tr>
     <td><strong>03</strong></td>
     <td>AFATINIB</td>
     <td>No adaptation</td>
     <td>No adaptation</td>
   </tr>
   <tr>
     <td><strong>04</strong></td>
     <td>AFLIBERCEPT</td>
     <td>No adaptation</td>
     <td>No adaptation</td>
   </tr>
   <tr>
     <td><strong>05</strong></td>
     <td>ALEMTUZUMAB</td>
     <td>No adaptation</td>
     <td>No adaptation</td>
   </tr>
   <tr>
     <td><strong>06</strong></td>
     <td>AMASACRINE</td>
     <td>CrCl &lt; 30 mL/min: 70%</td>
     <td>
       <ul>
         <li>Bili &gt; 20mg/l: 60 -70%</li>
         <li>&gt; 36mg/l: 50 % or not recommended</li>
       </ul>
     </td>
   </tr>
   <tr>
     <td><strong>07</strong></td>
     <td>ASPARAGINASE</td>
     <td>No adaptation</td>
     <td>&gt; 36mg/l: CI</td>
   </tr>
   <tr>
     <td><strong>08</strong></td>
     <td>AXITINIB</td>
     <td>No adaptation</td>
     <td>No adaptation</td>
   </tr>
   <tr>
     <td><strong>09</strong></td>
     <td>AZACITIDINE</td>
     <td>Creatininemie &ge; 14-26 mg/L for men and 10-24 mg/L for women: 50%</td>
     <td>No adaptation</td>
   </tr>
   <tr>
     <td><strong>10</strong></td>
     <td>BENDAMUSTINE</td>
     <td>CrCl &lt; 40 mL/min: CI</td>
     <td>
       <ul>
         <li>Bili &lt; 12 mg/l: NA</li>
         <li>Bili 12mg/l &ndash; 30mg/l: 70%</li>
         <li>Bili &gt; 30mg/l : CI</li>
       </ul>
     </td>
   </tr>
   <tr>
    <td><strong>11</strong></td>
    <td>BEVACIZUMAB</td>
    <td>No adaptation</td>
    <td>No adaptation</td>
   </tr>
   <tr>
    <td><strong>12</strong></td>
    <td>BLEOMYCINE</td>
    <td>
     <ul>
         <li>CrCl &lt; 50 mL/min: 70%</li>
         <li>CrCl &lt; 40 mL/min: 60%</li>
         <li>CrCl &lt; 30 mL/min: 55%</li>
         <li>CrCl &lt; 20 mL/min: 45%</li>
         <li>CrCl &lt; 10 mL/min: 40%</li>
     </ul>
    </td>
    <td>No adaptation</td>
   </tr>
   <tr>
    <td><strong>13</strong></td>
    <td>BLINATUMOMAB</td>
    <td>No adaptation</td>
    <td>No adaptation</td>
   </tr>
   <tr>
    <td><strong>14</strong></td>
    <td>BORTEZOMIB</td>
    <td>No adaptation</td>
    <td>
     <ul>
       <li>Bili &le;18mg/l: NA</li>
       <li>Bili &gt;18mg/l: 50%</li>
     </ul>
    </td>
   </tr>
   <tr>
    <td><strong>15</strong></td>
    <td>BRENTUXIMAB</td>
    <td>
     <ul>
       <li>CrCl &lt; 30 mL/min: 1,2 mg/k</li>
       <li>CrCl&nbsp; &lt; 15 mL/min: CI</li>
     </ul>
    </td>
    <td>
     <ul>
       <li>Bili: 12- 18mg/l: 66%</li>
       <li>Bili &gt;18- 36mg/L: CI</li>
     </ul>
    </td>
   </tr>
   <tr>
    <td><strong>16</strong></td>
    <td>CABAZITAXEL</td>
    <td>No adaptation</td>
    <td>
     <ul>
       <li>Bili&nbsp;: 12- 18mg/l&nbsp;or ASAT H&gt;40UI/L F &gt;38UI/L: 80%</li>
       <li>Bili 18- 36mg/L:60%</li>
       <li>&gt; 36mg/l: CI</li>
     </ul>
    </td>
   </tr>
   <tr>
    <td><strong>17</strong></td>
    <td>CAPECITABINE</td>
    <td>
     <ul>
       <li>CrCl &lt; 50 mL/min: 75 %</li>
       <li>CrCl &lt; 30 mL/min: CI</li>
     </ul>
    </td>
    <td>No adaptation</td>
   </tr>
   <tr>
    <td><strong>18</strong></td>
    <td>CARBOPLATINE</td>
    <td>CALVERT</td>
    <td>No adaptation</td>
   </tr>
   <tr>
    <td><strong>19</strong></td>
    <td>CARFILOZOMIB</td>
    <td>CrCl &lt; 15 mL/min: 50%</td>
    <td>
     <ul>
       <li>Bili 12mg/l &ndash; 36mg/l: 75%</li>
       <li>&gt; 36mg/l: CI</li>
     </ul>
    </td>
   </tr>
   <tr>
    <td><strong>20</strong></td>
    <td>CETUXIMAB</td>
    <td>No adaptation</td>
    <td>No adaptation</td>
   </tr>
   <tr>
    <td><strong>21</strong></td>
    <td>CHLORAMBUCIL</td>
    <td>
     <ul>
       <li>CrCl &lt; 60 mL/min: 1,5 to 9mg/day</li>
       <li>CrCl &lt; 15 mL/min: 1 to 6 mg/day</li>
     </ul>
    </td>
    <td>No adaptation</td>
   </tr>
   <tr>
    <td><strong>22</strong></td>
    <td>CISPLATINE</td>
    <td>
     <ul>
       <li>CrCl &lt; 60 mL/min: 50 %</li>
       <li>CrCl &lt; 45 mL/min: 25 %</li>
       <li>CrCl &le; 30 mL/min: CI</li>
     </ul>
    </td>
    <td>No adaptation</td>
   </tr>
   <tr>
    <td><strong>23</strong></td>
    <td>CLADRIBINE</td>
    <td>
     <ul>
       <li>CrCl &lt; 50 mL/min: 75%</li>
       <li>CrCl &lt; 10 mL/min: 50%</li>
     </ul>
    </td>
    <td>No adaptation</td>
   </tr>
   <tr>
    <td><strong>24</strong></td>
    <td>CRISANTASPASE</td>
    <td>No adaptation</td>
    <td>BILI &gt;12mg/l: CI</td>
   </tr>
   <tr>
    <td><strong>25</strong></td>
    <td>CRIZOTINIB</td>
    <td>CrCl &le; 30 mL/min: 250 mg daily (no dialysis required), the dosage may be increased to 200 mg twice daily based on individual safety and tolerance.</td>
    <td>BILI &gt;12mg/l: CI</td>
   </tr>
   <tr>
    <td><strong>26</strong></td>
    <td>CYCLOPHOSPHAMIDE</td>
    <td>CrCl &lt; 10 mL/min: 50 %</td>
    <td>
     <ul>
       <li>T.Bil &gt; 31&ndash;50 mg/L or AST &gt; 180 IU/L: 75%</li>
       <li>T.Bil &gt; 50 mg/L: CI</li>
     </ul>
    </td>
   </tr>
   <tr>
    <td><strong>27</strong></td>
    <td>CYTARABINE</td>
    <td>
     <ul>
       <li>CrCl &lt; 60 mL/min: 50%</li>
       <li>CrCl &lt; 40 mL/min: 25 %</li>
     </ul>
    </td>
    <td>No adaptation</td>
   </tr>
   <tr>
    <td><strong>28</strong></td>
    <td>DACARBAZINE</td>
    <td>
     <ul>
       <li>CrCl &lt; 60 mL/min: 75%</li>
       <li>CrCl &lt; 30 mL/min: 50%</li>
       <li>CrCl &lt; 10 mL/min: CI</li>
     </ul>
    </td>
    <td>T.Bil &gt; 36mg/l: CI</td>
   </tr>
   <tr>
    <td><strong>29</strong></td>
    <td>DACTINOMYCINE</td>
    <td>No adaptation</td>
    <td>No adaptation</td>
   </tr>
   <tr>
    <td><strong>30</strong></td>
    <td>DASATINIB</td>
    <td>No adaptation</td>
    <td>No adaptation</td>
   </tr>
   <tr>
    <td><strong>31</strong></td>
    <td>DAUNORUBICINE</td>
    <td>Creatininemie &gt; 30 mg/L: 50%</td>
    <td>
     <ul>
       <li>T.Bil 15&ndash;30 mg/L or AST 60&ndash;180 IU/L: 75%</li>
       <li>T.Bil &gt; 31&ndash;50 mg/L or AST &gt; 180 IU/L: 50%</li>
       <li>T.Bil &gt; 50 mg/L: CI</li>
     </ul>
    </td>
   </tr>
   <tr>
    <td><strong>32</strong></td>
    <td>DENOSUMAB</td>
    <td>No adaptation</td>
    <td>No adaptation</td>
   </tr>
   <tr>
    <td><strong>33</strong></td>
    <td>DOXORUBICINE</td>
    <td>CrCl &lt; 10 mL/min: 75%</td>
    <td>
     <ul>
       <li>T.Bil 15&ndash;30 mg/L or AST 60&ndash;180 IU/L: 50%</li>
       <li>T.Bil &gt; 31&ndash;50 mg/L or AST &gt; 180 IU/L: 25%</li>
       <li>T.Bil &gt; 50 mg/L: CI</li>
     </ul>
    </td>
   </tr>
   <tr>
    <td><strong>34</strong></td>
    <td>DOCETAXEL</td>
    <td>No adaptation</td>
    <td>
     <ul>
       <li>ASAT H&gt;60UI/L F &gt;48UI/L or PAL H&gt;325 UI/L F &gt;262,5UI/L: 75%</li>
       <li>Bili &gt;12mg/l and/or [asat&nbsp; H&gt; 140 UI/L F &gt;112 UI/L with PAL H &gt;780UI/L&nbsp; F&gt; 630UI/L]: CI</li>
     </ul>
    </td>
   </tr>
   <tr>
    <td><strong>35</strong></td>
    <td>ENZALUTAMIDE</td>
    <td>No adaptation</td>
    <td>No adaptation</td>
   </tr>
   <tr>
    <td><strong>36</strong></td>
    <td>EPIRUBICINE</td>
    <td>No adaptation</td>
    <td>
     <ul>
       <li>Bili 12-30mg/l or asat (H 80UI/L F 64UI/L &ndash; H160UI/L&nbsp; F128UI/L): 50%</li>
       <li>Bili &gt; 30mg/l or asat H160UI/L&nbsp; F128UI/L: 25%</li>
       <li>Bili&gt; 36mg/l: CI</li>
     </ul>
    </td>
   </tr>
   <tr>
    <td><strong>37</strong></td>
    <td>ERIBULINE</td>
    <td>CrCl&nbsp; &lt; 50 mL/min: 80%</td>
    <td>BILI &gt;36mg/l: CI</td>
   </tr>
   <tr>
    <td><strong>38</strong></td>
    <td>ERLOTINIB</td>
    <td>CrCl &lt; 10 mL/min: CI</td>
    <td>
     <ul>
       <li>AST H &ge; 120 UI/L&nbsp; F &ge;96UI/L or T.Bil 1&ndash;7 mg/L: &nbsp;50%</li>
       <li>T.Bil &gt; 70 mg/L: CI</li>
     </ul>
    </td>
   </tr>
   <tr>
    <td><strong>39</strong></td>
    <td>ETOPOSIDE</td>
    <td>
     <ul>
       <li>CrCl &lt; 50 mL/min: 75%</li>
       <li>CrCl &lt; 15 mL/min: CI</li>
     </ul>
    </td>
    <td>
     <ul>
       <li>T.Bil 15&ndash;30mg/L or AST 60&ndash;180 UI/L: 50%</li>
       <li>T.Bil &ge; 30 mg/L or AST &gt; 180 UI/L: CI</li>
     </ul>
    </td>
   </tr>
   <tr>
    <td><strong>40</strong></td>
    <td>EVEROLIMUS</td>
    <td>No adaptation</td>
    <td>No adaptation</td>
   </tr>
   <tr>
    <td><strong>41</strong></td>
    <td>FLUDARABINE</td>
    <td>
     <ul>
       <li>CrCl &lt; 70 mL/min: 50%</li>
       <li>CrCl &lt; 30 mL/min: CI</li>
     </ul>
    </td>
    <td>No adaptation</td>
   </tr>
   <tr>
    <td><strong>42</strong></td>
    <td>FLUOROURACILE</td>
    <td>No adaptation</td>
    <td>T.Bil &gt; 50 mg/L: CI</td>
   </tr>
   <tr>
    <td><strong>43</strong></td>
    <td>FULVESTRANT</td>
    <td>No adaptation</td>
    <td>No adaptation</td>
   </tr>
   <tr>
    <td><strong>44</strong></td>
    <td>GEFITINIB</td>
    <td>No adaptation</td>
    <td>No adaptation</td>
   </tr>
   <tr>
    <td><strong>45</strong></td>
    <td>GEMCITABINE</td>
    <td>No adaptation</td>
    <td>
     <ul>
       <li>Asat H &gt;40UI/L, F&gt;32UI/L: No adaptation</li>
       <li>T.Bil&gt;12mg/L: 80%</li>
     </ul>
    </td>
   </tr>
   <tr>
    <td><strong>46</strong></td>
    <td>HYDROXYCARBAMIDE</td>
    <td>
     <ul>
       <li>CrCl &lt;&nbsp; 60 mL/min: 75%</li>
       <li>CrCl &lt; 10 mL/min: 50%</li>
     </ul>
    </td>
    <td>
     <ul>
       <li>T.bili 15-50mg/L or Asat 60-180IU/L: 50%</li>
       <li>T.bili &gt;50mg/l or Asat &gt; 180 UI&nbsp;/l: CI</li>
     </ul>
    </td>
   </tr>
   <tr>
    <td><strong>47</strong></td>
    <td>IBRUTINIB</td>
    <td>No adaptation</td>
    <td>No adaptation</td>
   </tr>
   <tr>
    <td><strong>48</strong></td>
    <td>IFOSFAMIDE</td>
    <td>
     <ul>
       <li>CrCl &lt; 60 mL/min: 80%</li>
       <li>CrCl &lt; 45 mL/min: 75%</li>
       <li>CrCl &lt; 30 mL/min: 70%</li>
       <li>CrCl &lt; 10 mL/min: CI</li>
     </ul>
    </td>
    <td>No adaptation</td>
   </tr>
   <tr>
    <td><strong>49</strong></td>
    <td>IMATINIB</td>
    <td>CrCl &lt; 60 mL/min: 400 mg</td>
    <td>T.Bil &gt;12mg/l: 400 mg</td>
   </tr>
   <tr>
    <td><strong>50</strong></td>
    <td>IRINOTECAN</td>
    <td>No adaptation</td>
    <td>
     <ul>
       <li>Increased AST: No adaptation.</li>
       <li>T.Bil 18mg/l &ndash;36 mg/l&nbsp; and ratio of AST to ALT &lt; 5 &times; ULN: 75%</li>
       <li>T.Bil 37,2 mg/l &ndash;60mg/l and ratio of AST to ALT &lt; 5 &times; ULN: 40%</li>
       <li>T.Bil &lt; 18 mg/l ratio of AST to ALT 5.1&ndash;20 &times; ULN: 75%</li>
       <li>T.Bil 18mg/l &ndash;36 mg/l&nbsp; and ratio of AST to ALT 5.1&ndash;20 &times; ULN: 30%</li>
     </ul>
    </td>
   </tr>
   <tr>
    <td><strong>51</strong></td>
    <td>IDARUBICINE</td>
    <td>No adaptation</td>
    <td>Bili &gt;36mg/l: CI</td>
   </tr>
   <tr>
    <td><strong>52</strong></td>
    <td>LANREOTIDE</td>
    <td>No adaptation</td>
    <td>No adaptation</td>
   </tr>
   <tr>
    <td><strong>53</strong></td>
    <td>LAPATINIB</td>
    <td>No adaptation</td>
    <td>No adaptation</td>
   </tr>
   <tr>
    <td><strong>54</strong></td>
    <td>LENALIDOMIDE</td>
    <td>
     <ul>
       <li>CrCl &lt;&nbsp; 60 mL/min: 10 mg every 24h.</li>
       <li>CrCl &lt; 30 mL/min (does not require dialysis): 15 mg every 48h.</li>
       <li>CrCl &lt; 30 mL/min (requires dialysis): 5 mg/day.</li>
     </ul>
    </td>
    <td>No adaptation</td>
   </tr>
   <tr>
    <td><strong>55</strong></td>
    <td>LENOGRASTIM</td>
    <td>No adaptation</td>
    <td>No adaptation</td>
   </tr>
   <tr>
    <td><strong>56</strong></td>
    <td>MELPHALAN</td>
    <td>
     <ul>
       <li>CrCl &lt; 60 mL/min: 85%</li>
       <li>CrCl &lt; 45 mL/min: 75%</li>
       <li>CrCl &lt; 30 mL/min: 70%</li>
       <li>CrCl &lt; 10 mL/min: 50%</li>
     </ul>
    </td>
    <td>No adaptation</td>
   </tr>
   <tr>
    <td><strong>57</strong></td>
    <td>MERCAPTOPURINE</td>
    <td>
     <ul>
       <li>CrCl &le; 50 mL/min: 50%</li>
       <li>CrCl &lt; 20 mL/min: CI</li>
     </ul>
    </td>
    <td>No adaptation</td>
   </tr>
   <tr>
    <td><strong>58</strong></td>
    <td>METHOTRAXATE</td>
    <td>
     <ul>
       <li>CrCl&nbsp; &lt; 50 mL/min: 50%</li>
       <li>CrCl&nbsp; &lt; 15 mL/min: CI</li>
     </ul>
    </td>
    <td>
     <ul>
       <li>T.Bil 31&ndash;50 mg/L or AST &gt; 180 IU/L: 75%</li>
       <li>T.Bil &gt; 50mg/L: CI</li>
     </ul>
    </td>
   </tr>
   <tr>
    <td><strong>59</strong></td>
    <td>MITOMYCINE</td>
    <td>
     <ul>
       <li>CrCl &lt; 60 mL/min: 75%</li>
       <li>CrCl &lt; 30 mL/min: 50%</li>
       <li>CrCl &lt; 10 mL/min: CI</li>
     </ul>
    </td>
    <td>No adaptation</td>
   </tr>
   <tr>
    <td><strong>60</strong></td>
    <td>NILOTINIB</td>
    <td>No adaptation</td>
    <td>No adaptation</td>
   </tr>
   <tr>
    <td><strong>61</strong></td>
    <td>NIMOTUZUMAB</td>
    <td>No adaptation</td>
    <td>No adaptation</td>
   </tr>
   <tr>
<td width="29">
<p><strong>62</strong></p>
</td>
<td width="170">
<p>NINTEDANIB</p>
</td>
<td width="179">
<p>No adaptation</p>
</td>
<td width="223">
<p>No adaptation</p>
</td>
</tr>
<tr>
<td width="29">
<p><strong>63</strong></p>
</td>
<td width="170">
<p>NIVOLUMAB</p>
</td>
<td width="179">
<p>No adaptation</p>
</td>
<td width="223">
<p>No adaptation</p>
</td>
</tr>
<tr>
<td width="29">
<p><strong>64</strong></p>
</td>
<td width="170">
<p>OXALIPLATINE</p>
</td>
<td width="179">
<p>CrCl &lt; 30 mL/min: CI</p>
</td>
<td width="223">
<p>No adaptation</p>
</td>
</tr>
<tr>
<td width="29">
<p><strong>65</strong></p>
</td>
<td width="170">
<p>PACLITAXEL</p>
</td>
<td width="179">
<p>No adaptation</p>
</td>
<td width="223">
<p>&bull; Asat H&lt; 400UI/L&nbsp;F&lt; 320 UI/L and bili 19,2mg/l -24mg/l: 77%</p>
<p>&bull; Asat H&lt; 400UI/L&nbsp;F&lt; 320 UI/L and bili 24,12mg/l -60mg/l: 51%</p>
<p>&bull; Asat H&ge; 400UI/L&nbsp;F&ge; 320 UI/L and bili &gt; 60mg/l: not recommended&nbsp;&nbsp;or CI</p>
</td>
</tr>
<tr>
<td width="29">
<p><strong>66</strong></p>
</td>
<td width="170">
<p>PALBOCICLIB</p>
</td>
<td width="179">
<p>No adaptation</p>
</td>
<td width="223">
<p>No adaptation</p>
</td>
</tr>
<tr>
<td width="29">
<p><strong>67</strong></p>
</td>
<td width="170">
<p>PANITUMUMAB</p>
</td>
<td width="179">
<p>No adaptation</p>
</td>
<td width="223">
<p>No adaptation</p>
</td>
</tr>
<tr>
<td width="29">
<p><strong>68</strong></p>
</td>
<td width="170">
<p>PAZOPANIB</p>
</td>
<td width="179">
<p>No adaptation</p>
</td>
<td width="223">
<p>No adaptation</p>
</td>
</tr>
<tr>
<td width="29">
<p><strong>69</strong></p>
</td>
<td width="170">
<p>PEMBROLIZUM</p>
</td>
<td width="179">
<p>No adaptation</p>
</td>
<td width="223">
<p>No adaptation</p>
</td>
</tr>
<tr>
<td width="29">
<p><strong>70</strong></p>
</td>
<td width="170">
<p>PEMETREXED</p>
</td>
<td width="179">
<p>CrCl &lt; 45 mL/min: CI</p>
</td>
<td width="223">
<p>No adaptation</p>
</td>
</tr>
<tr>
<td width="29">
<p><strong>71</strong></p>
</td>
<td width="170">
<p>PERTUZUMAB</p>
</td>
<td width="179">
<p>No adaptation</p>
</td>
<td width="223">
<p>No adaptation</p>
</td>
</tr>
<tr>
<td width="29">
<p><strong>72</strong></p>
</td>
<td width="170">
<p>PRALATREXATE</p>
</td>
<td width="179">
<p>No adaptation</p>
</td>
<td width="223">
<p>No adaptation</p>
</td>
</tr>
<tr>
<td width="29">
<p><strong>73</strong></p>
</td>
<td width="170">
<p>PROCARBAZINE</p>
</td>
<td width="179">
<p>CrCl &le; 30 mL/min: CI</p>
</td>
<td width="223">
<p>No adaptation</p>
</td>
</tr>
<tr>
<td width="29">
<p><strong>74</strong></p>
</td>
<td width="170">
<p>RAMUCIRUMAB</p>
</td>
<td width="179">
<p>No adaptation</p>
</td>
<td width="223">
<p>No adaptation</p>
</td>
</tr>
<tr>
<td width="29">
<p><strong>75</strong></p>
</td>
<td width="170">
<p>REGORAFENIB</p>
</td>
<td width="179">
<p>No adaptation</p>
</td>
<td width="223">
<p>No adaptation</p>
</td>
</tr>
<tr>
<td width="29">
<p><strong>76</strong></p>
</td>
<td width="170">
<p>RITUXIMAB</p>
</td>
<td width="179">
<p>No adaptation</p>
</td>
<td width="223">
<p>No adaptation</p>
</td>
</tr>
<tr>
<td width="29">
<p><strong>77</strong></p>
</td>
<td width="170">
<p>ROMIPLOSTIME</p>
</td>
<td width="179">
<p>No adaptation</p>
</td>
<td width="223">
<p>No adaptation</p>
</td>
</tr>
<tr>
<td width="29">
<p><strong>78</strong></p>
</td>
<td width="170">
<p>SORAFENIB</p>
</td>
<td width="179">
<p>No adaptation</p>
</td>
<td width="223">
<p>No adaptation</p>
</td>
</tr>
<tr>
<td width="29">
<p><strong>79</strong></p>
</td>
<td width="170">
<p>SUNITINIB</p>
</td>
<td width="179">
<p>No adaptation</p>
</td>
<td width="223">
<p>No adaptation</p>
</td>
</tr>
<tr>
<td width="29">
<p><strong>80</strong></p>
</td>
<td width="170">
<p>TARSTUZUMAB EMTANSINE</p>
</td>
<td width="179">
<p>No adaptation</p>
</td>
<td width="223">
<p>No adaptation</p>
</td>
</tr>
<tr>
<td width="29">
<p><strong>81</strong></p>
</td>
<td width="170">
<p>TEMOZOLOMIDE</p>
</td>
<td width="179">
<p>No adaptation</p>
</td>
<td width="223">
<p>No adaptation</p>
</td>
</tr>
<tr>
<td width="29">
<p><strong>82</strong></p>
</td>
<td width="170">
<p>THALIDOMIDE</p>
</td>
<td width="179">
<p>No adaptation</p>
</td>
<td width="223">
<p>No adaptation</p>
</td>
</tr>
<tr>
<td width="29">
<p><strong>83</strong></p>
</td>
<td width="170">
<p>TRASTUZUMAB</p>
</td>
<td width="179">
<p>No adaptation</p>
</td>
<td width="223">
<p>No adaptation</p>
</td>
</tr>
<tr>
<td width="29">
<p><strong>84</strong></p>
</td>
<td width="170">
<p>TRETINOINE</p>
</td>
<td width="179">
<p>reduit a 25 mg/m&sup2;/jour</p>
</td>
<td width="223">
<p>No adaptation</p>
</td>
</tr>
<tr>
<td width="29">
<p><strong>85</strong></p>
</td>
<td width="170">
<p>TRI OXYDE D'ARSENIC</p>
</td>
<td width="179">
<p>No adaptation</p>
</td>
<td width="223">
<p>No adaptation</p>
</td>
</tr>
<tr>
<td width="29">
<p><strong>86</strong></p>
</td>
<td width="170">
<p>VEMURAFENIB</p>
</td>
<td width="179">
<p>No adaptation</p>
</td>
<td width="223">
<p>No adaptation</p>
</td>
</tr>
<tr>
<td width="29">
<p><strong>87</strong></p>
</td>
<td width="170">
<p>VINBLASTINE</p>
</td>
<td width="179">
<p>No adaptation</p>
</td>
<td width="223">
<p>&bull; T.Bil 15&ndash;30 mg/dL or ASAT 60&ndash;180 IU/L: 50%</p>
<p>&bull; T.Bil &gt; 31 mg/L or AST &gt; 180 IU/L: CI</p>
</td>
</tr>
<tr>
<td width="29">
<p><strong>88</strong></p>
</td>
<td width="170">
<p>VINCRISTINE</p>
</td>
<td width="179">
<p>No adaptation</p>
</td>
<td width="223">
<p>No adaptation</p>
</td>
</tr>
<tr>
<td width="29">
<p><strong>89</strong></p>
</td>
<td width="170">
<p>VINFLUNINE</p>
<p>&nbsp;</p>
<p>&nbsp;</p>
<p>&nbsp;</p>
</td>
<td width="179">
<p>&bull; CrCl&nbsp; &lt; 60 mL/min: 87,5%</p>
<p>&bull; 20 &lt; CrCl&nbsp; &lt; 40 mL/min: 75%</p>
</td>
<td width="223">
<p>&bull; Asat H&gt; 40UI/L F&gt; 32 UI/L and bili&gt;18mg/l: 78%</p>
<p>&bull; Asat H&gt; 40UI/L F&gt;32 UI/L and bili&gt;36mg/l: 62%</p>
<p>&bull; Asat H&ge; 100UI/L F&ge; 80 UI/L and bili &gt; 60mg/l: CI</p>
</td>
</tr>
<tr>
<td width="29">
<p><strong>90</strong></p>
</td>
<td width="170">
<p>VINORELBINE</p>
</td>
<td width="179">
<p>No adaptation</p>
</td>
<td width="223">
<p>&bull; T.Bil 25,2 mg/l &ndash;36mg/l: 50%</p>
<p>&bull; T.Bil &gt; 36mg/l: 25%</p>
</td>
</tr>
<tr>
<td width="29">
<p><strong>91</strong></p>
</td>
<td width="170">
<p>VISMODEGIB</p>
</td>
<td width="179">
<p>No adaptation</p>
</td>
<td width="223">
<p>No adaptation</p>
</td>
</tr>
</tbody>
</table>
